| TA192 |
Lung cancer (non-small-cell, first line) - gefitinib (TA192) |
|
-
-
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
NICE recommends gefitinib as a possible first treatment for some people with locally advanced or metastatic non-small-cell lung cancer (see below).
Who can have gefitinib?You should be able to have gefitinib if:
- you have a type of locally advanced or metastatic non-small-cell lung cancer that responds to gefitinib treatment and
- you have not had drug treatment for non-small-cell lung cancer before.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended gefitinib because it is a new type of treatment for locally advanced or metastatic non-small-cell lung cancer which works as well as other treatments available on the NHS and costs about the same.-
Other information
How this guidance was produced
Background information
- None found
This page was last updated: 13 December 2011
-
Guidance formats
-
Implementation tools and resources
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
